New weapon targets common cancer marker in early human trial
Disease control
Not yet recruiting
This is a first-in-human study to test the safety and find the right dose of a new experimental drug called ONC-783. It will involve about 20 adults with advanced solid tumors, focusing on colorectal, ovarian, pancreatic, or breast cancers. The drug is designed to guide the body'…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC